Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03217656
Recruiting Observational

The Jiaxing Birth Cohort in China

NCT03217656 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang University
Phase
Observational
Started
1999-01
Last updated
2018-01-23

Condition(s) studied

Childhood ObesityAnemiaPregnancy ComplicationsPregnancy; HypertensionFeeding Behavior

Investigational drug(s) / intervention(s)

No intervention

Study summary

The Jiaxing Birth Cohort (JBC) is the largest prospective cohort study to explore prenatal risk factors, early life feeding practice and growth pattern/ adiposity in Chinese children.Between 1999 and 2013, 338 413 mother-child pairs were recruited in Jiaxing area in south-east China.Children of the recruited women were followed up at 1-2, 3, 6, 9 and 12 months of age, and subsequently followed up every 6 months to 36 months of age (toddler stage), and every year to 6-7 years of age before they went to school (pre-school stage). Follow-up rate was 70.8% at the toddler stage and 68.9% at the pre-school stage up to June 2013.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Pregnant women came to clinic visit at one of the local hospitals during pregnancy at Jiaxing area 2. Pregnant women were followed up during pregnancy and their children were born alive at local hospital or clinics Exclusion Criteria: 1. Those who did not want to participant 2. The infant was dead at the birth 3. Those pregnant mothers who dropped out during follow-up at pregnancy or moved out of the Jiaxing area

Primary outcome measure(s)

  • overweight and obesity — Up to 6-7 years old for these children
    BMI-z-score was calculated from height and weight. BMI-z-score\>1 was defined as overweight/obesity

Trial sites (1)

FacilityCityRegionStatus
Zhejiang University Hangzhou Zhejiang Recruiting

More Zhejiang University trials in China

A Study to Evaluate Safety and Feasibility of Robotic Liver Resection Recruiting
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer Recruiting
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor Active, not recruiting
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China Recruiting
Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors Recruiting

Other trials for the same condition

Time Restricted Eating in Childhood Obesity (TRECO) Recruiting
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia Recruiting
Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. Recruiting
Maternal Grandmothers in the Born in Guangzhou Cohort Study Recruiting
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03217656 on ClinicalTrials.gov ↗ ← All trials in China